Kymera Therapeutics (NASDAQ:KYMR) Issues Quarterly Earnings Results

Kymera Therapeutics (NASDAQ:KYMR) issued its quarterly earnings results on Wednesday. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.09, FiscalAI reports. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The company had revenue of $65.00 million for the quarter, compared to the consensus estimate of $32.78 million. During the same period in the previous year, the business posted ($0.95) EPS. The company’s revenue for the quarter was up 465.2% on a year-over-year basis.

Here are the key takeaways from Kymera Therapeutics’ conference call:

• KT-621’s atopic dermatitis Phase IIb trial completed enrollment six months early, with top-line data now expected by year-end 2026 and Phase III initiation targeted for mid-2027. Management believes the oral, once-daily profile could substantially expand systemic treatment in type 2 inflammatory diseases.
• The asthma Phase IIb trial is enrolling and remains on track for top-line results by late 2027, while an open-label extension will provide up to 52 additional weeks of safety and efficacy data. The company also expects KT-579 healthy-volunteer data in Q4 2026 before advancing into lupus proof-of-concept studies.
• Partnered programs continue to advance, including Sanofi’s KT-485 Phase I start, which generated a $20 million milestone, and Gilead’s $45 million option exercise fee. Gilead’s KT-200 is expected to enter clinical development next year.
• Kymera ended June with approximately $1.5 billion in cash and investments and reiterated a cash runway into 2029. Management expects this funding to support current Phase II programs, KT-579 through lupus proof of concept, and the beginnings of KT-621 Phase III development.
• The company recognized all currently deferred collaboration revenue in the second quarter, totaling $65 million, and does not expect additional revenue in 2026 absent new milestones. R&D cash spending rose 22% sequentially to $109.1 million as clinical investment increases.

Kymera Therapeutics Trading Up 0.1%

KYMR stock traded up $0.07 during midday trading on Wednesday, hitting $104.46. The stock had a trading volume of 260,200 shares, compared to its average volume of 738,681. The firm has a market capitalization of $8.59 billion, a price-to-earnings ratio of -29.24 and a beta of 1.95. Kymera Therapeutics has a 52 week low of $36.65 and a 52 week high of $130.05. The stock has a 50-day simple moving average of $99.82 and a 200 day simple moving average of $88.16.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on KYMR shares. B. Riley Financial boosted their target price on shares of Kymera Therapeutics from $117.00 to $155.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Royal Bank Of Canada downgraded shares of Kymera Therapeutics from an “outperform” rating to a “sector perform” rating and increased their price target for the company from $106.00 to $115.00 in a report on Monday, July 13th. Wall Street Zen upgraded shares of Kymera Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 2nd. Guggenheim boosted their price objective on shares of Kymera Therapeutics from $125.00 to $135.00 and gave the stock a “buy” rating in a report on Tuesday, July 28th. Finally, BTIG Research reaffirmed a “buy” rating and set a $134.00 price objective on shares of Kymera Therapeutics in a research report on Thursday, June 25th. Twenty equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Kymera Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $124.48.

Insider Activity

In other Kymera Therapeutics news, Director Bruce Booth sold 31,283 shares of the business’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $109.48, for a total value of $3,424,862.84. Following the sale, the director owned 461,794 shares of the company’s stock, valued at $50,557,207.12. The trade was a 6.34% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Nello Mainolfi sold 50,000 shares of the stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $119.00, for a total transaction of $5,950,000.00. Following the completion of the transaction, the chief executive officer owned 666,568 shares of the company’s stock, valued at approximately $79,321,592. This represents a 6.98% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 3,607,813 shares of company stock valued at $387,818,004. 15.98% of the stock is owned by insiders.

Institutional Trading of Kymera Therapeutics

Hedge funds have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Kymera Therapeutics by 6.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,793 shares of the company’s stock valued at $849,000 after buying an additional 1,833 shares in the last quarter. Millennium Management LLC lifted its position in Kymera Therapeutics by 340.4% during the 1st quarter. Millennium Management LLC now owns 510,480 shares of the company’s stock worth $13,972,000 after buying an additional 394,562 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Kymera Therapeutics by 121.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock worth $24,535,000 after buying an additional 491,737 shares in the last quarter. Invesco Ltd. grew its holdings in Kymera Therapeutics by 13.8% during the 2nd quarter. Invesco Ltd. now owns 47,884 shares of the company’s stock worth $2,090,000 after acquiring an additional 5,809 shares during the last quarter. Finally, Sei Investments Co. bought a new stake in Kymera Therapeutics during the 2nd quarter worth about $265,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.